相关实验视频

Updated: May 13, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

DNMT3A突变不太可能影响患有真菌多细胞血症的患者的干扰素α治疗结果

Ghaith Abu-Zeinah¹, Katie Erdos¹, Neville Lee²

¹Weill Cornell Medicine, New York, New York, United States.

|April 15, 2025

概括

在多细胞血症患者的DNA甲基转移酶3α (DNMT3A) 突变没有影响治疗结果. 这些突变在接受干扰素α (IFN) 治疗的患者中并不比较常见.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

血清多细胞 (PV) 是一种骨髓增殖性新生体,其特征是红细胞的生产增加.
在DNA甲基转移酶3α (DNMT3A) 基因的突变被观察到在各种血液恶性瘤中.
在PV病原和治疗反应中DNMT3A突变的作用需要进一步阐明.

研究的目的:

调查DNMT3A突变在多细胞真血病 (PV) 患者中的患病率和临床意义.
为了确定DNMT3A突变是否与PV的特定临床特征或治疗反应有关.
评估DNMT3A突变对PV血液学,分子学和生存结果的影响.

主要方法:

从PV患者的外周血液样本中提取基因组DNA.
下一代测序 (NGS) 或桑格测序用于检测DNMT3A突变.
DNMT3A突变状态和临床数据之间的相关性分析,包括用干扰素α (IFN) 治疗.

主要成果:

在一小部分PV患者中发现了DNMT3A突变,这些突变表现出异质的突变模式.
在接受干扰素-α (IFN) 治疗的患者中,没有观察到DNMT3A突变的显著丰富.
DNMT3A突变没有对血液学反应,分子反应率或整体存活率产生统计学上显著的影响.

结论:

在PV患者中DNMT3A突变是异质的,并且似乎不受干扰素α (IFN) 治疗的影响.
DNMT3A突变的存在不会预测或影响血液学反应,分子缓解或多细胞血症真实存活结果.

更多相关视频

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...